Immunogenic cell death

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
MIBC, FDA, Cancer, Urology, Fast Track, Necrosis, SPA, Safety, General counsel, Research, Recurrence, Growth, Light, Bladder cancer, Immunogenic cell death, Incidence, Patient, Enrollment, Compass, Macrophage, NMIBC, Neoplasm, Annual general meeting, Damage-associated molecular pattern, ARVO, Pharmaceutical industry

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

Key Points: 
  • Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024
    BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.
  • “Throughout the first quarter of 2024, the Company made significant progress across our ocular and urologic oncology therapeutic area programs,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • As of March 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $202.9 million.
  • General and administrative expenses include $1.4 million and $1.1 million of stock-based compensation for the three months ended March 31, 2024 and 2023, respectively.

Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting

Retrieved on: 
Giovedì, Aprile 11, 2024
Autophagy, Endoplasmic reticulum, Calreticulin, Mouse, Cell, Neck, HMGB1, Apoptosis, Research, ATP, Immunogenic cell death, Chung, Head, Vaccine

Titled PV-10 triggers immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma via endoplasmic reticulum stress and autophagy, a copy of Moffitt’s poster presentation is available on Provectus’s website at: https://www.provectusbio.com/media/docs/publications/AACR-poster-3-Apr-2... .

Key Points: 
  • Titled PV-10 triggers immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma via endoplasmic reticulum stress and autophagy, a copy of Moffitt’s poster presentation is available on Provectus’s website at: https://www.provectusbio.com/media/docs/publications/AACR-poster-3-Apr-2... .
  • Moffitt observed that PV-10 induced reactive oxygen species-mediated apoptosis, surface expression of calreticulin, and extracellular ATP and HMGB1 release in HNSCC cells.
  • PV-10-induced immunogenic cell death (“ICD”) led to surface expression of HSP-70 and HSP-90 in these cells.
  • Intralesional (“IL”) injection of PV-10 promoted tumor regression in mice by inducing endoplasmic reticulum stress, triggering autophagy, and initiating apoptosis.

Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment

Retrieved on: 
Martedì, Aprile 9, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Pharma, Blood, Doxorubicin, Oxaliplatin, Breast, San Diego Convention Center, CDX, Prostate cancer, Death domain, Therapy, Immunogenic cell death, Patient, Neoplasm, ICD, Lung, Toxicity, AACR, Immune system, Carboplatin, Ovarian cancer, CD95, Vaccine

N17350 and N17465 are novel first-in-class oncology programs that harness the potent efficacy of the innate immune system and have the potential to become a major new treatment modality for a wide range of cancer types.

Key Points: 
  • N17350 and N17465 are novel first-in-class oncology programs that harness the potent efficacy of the innate immune system and have the potential to become a major new treatment modality for a wide range of cancer types.
  • Lev Becker, Ph.D., Scientific Founder, Onchilles Pharma, said, “We are excited to unveil systemically delivered N17465 that has the potential to redefine the treatment of solid tumors.
  • The data presented today demonstrate that N17465 exhibits potent and tumor-selective efficacy, mobilizes the immune system for anti-tumor immunity, and produces durable responses in mouse models as a monotherapy.
  • We are confident that N17350 and N17465 represent a novel class of molecules that could become the new foundation of cancer treatment.

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Venerdì, Aprile 5, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical trial, PDT, Macrophage, Downregulation and upregulation, Ovarian cancer, BRCA, ECM, Pericyte, Apoptosis, Nanoparticle, Cervical cancer, GBM, Patient, Neoplasm, Doxorubicin, Traffic barrier, Cancer, Triple-negative breast cancer, Proteomics, AACR, Glioblastoma, Pancreatic cancer, Phenotype, PARP, Cisplatin, Immunogenic cell death, Large intestine, TNBC, Animal, PDGFR, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
  • Presentations from Novocure-sponsored and partner programs include:
    Tumor Treating Fields (TTFields) targeted self assembling nanoparticles for pancreatic cancer treatment: In vitro and in vivo assessment.
  • Tumor Treating Fields (TTFields) induce an anti-tumor immune response in a pancreatic cancer mouse model.
  • Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib.

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Retrieved on: 
Giovedì, Marzo 7, 2024
Head, Neck, Chung, Calreticulin, Vaccine, Immunogenic cell death, Endoplasmic reticulum, ICD, HMGB1, Reactive oxygen species, ATP, Poster, Autophagy, Research, Mouse, Abstract

The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).

Key Points: 
  • The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).
  • According to Moffitt’s abstract, “…in vitro findings reveal that PV-10 induces cytotoxicity in both mEER and MTE-RAS cells.
  • Notably, PV-10 promotes a significant increase in [reactive oxygen species], leading to an elevation in late apoptotic cells.
  • At the molecular level, a remarkable activation of endoplasmic reticulum (ER) stress, pro-apoptotic protein, and autophagy markers were observed.

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Martedì, Febbraio 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Martedì, Febbraio 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

EQS-News: DEFENCE’S SUCCESSFUL SUBMISSION OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ACCUTOX® AS AN INJECTABLE ANTICANCER TREATMENT FOR SOLID TUMORS

Retrieved on: 
Sabato, Dicembre 30, 2023
Toxicology, Food, Immune system, Biotechnology, IND, Breast cancer, Drug discovery, USOTC, FDA, Immunogenic cell death, City, Melanoma, DNA, Human, Therapy, Cancer, Pharmacokinetics, Investigational New Drug, Animal, Neoplasm, BMS, DNA repair, DTC, Genome, Patient, Pharmacology, Pharmaceutical industry

AccuTOX® is a derivative of the initial Accum® molecule, which has been reported to target cancer on multiple fronts.

Key Points: 
  • AccuTOX® is a derivative of the initial Accum® molecule, which has been reported to target cancer on multiple fronts.
  • In addition, the application describes the manufacture of the drug substance and drug product to be used in human clinical trials.
  • “We are thrilled and excited that Defence has achieved a successful submission on its first IND, which represents an important milestone towards advancing AccuTOX® into the clinic.
  • Several other secondary parameters including therapeutic efficacy will be monitored in treated patients in preparation for a Phase IIa trial on a basket of tumors.

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate

Retrieved on: 
Giovedì, Dicembre 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MMAE, GMP, Immunogenic cell death, ITF, CDMO, MDR, Doctor of Pharmacy, Peptide, Multimedia, Bystander effect, Neoplasm, Medicine, DXD, NMS, Doctor of Philosophy, PDC, Fine chemical, Vaccine, Trastuzumab deruxtecan

(NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC).

Key Points: 
  • (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC).
  • View the full release here: https://www.businesswire.com/news/home/20231214543204/en/
    Under the terms of the agreement, ITF will use NMS’s proprietary linker-payload technology to develop a novel PDC product candidate.
  • This is a significant step to broaden the applicability of our technology,” said Hugues Dolgos, PharmD, Chief Executive Officer of NMS and NMS Group.
  • The development program will leverage NMS’s proprietary innovative linker-payload platform technology and ITF’s peptide-based oncology therapeutics technology.

Sonata Therapeutics Presents Data Supporting its Network Medicines™ Approach at SITC 2023

Retrieved on: 
Venerdì, Novembre 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Survival, Mouse, Immunogenic cell death, ICD, Therapy, Society for Immunotherapy of Cancer, Cytokine, Lipid peroxidation, Sonata, MBA, Network medicine, SITC, San Diego Convention Center, Immunotherapy, Cell death, Cancer, Ferroptosis, Sarcoma, Chemokine, Annual general meeting, Messenger, Champalimaud Foundation, Society, Ground Level, Drug resistance, Synthetic biology, Pharmaceutical industry, Vaccine, Medical imaging

Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • In contrast, Sonata’s Network Medicines target pathways that change the complete dynamics of multifactorial diseases, resulting in more durable therapeutics and potentially better outcomes for patients.
  • Data demonstrate that ferroptosis induction is a promising strategy for the treatment of sarcomas, supporting Sonata’s continued investigation in syngeneic mouse models.
  • “Through our proprietary platform, Sonata is generating Network Medicines that move beyond the current immunotherapeutic paradigm.